ArticleDiabetology international2025
Impact of concomitant use of antiplatelet agents on the production of anti-insulin antibodies in patients with type 2 diabetes treated with insulin analogues.
Article in Diabetology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: We have already reported that anti-insulin antibodies are produced at a fairly high frequency in type 2 diabetic patients treated with insulin analogues, and the amount of insulin requirement was significantly higher in antibodies carriers than in non-carriers. On the other hand, insulin autoantibody production by clopidogrel, which has an antiplatelet effect, has been reported. Therefore, we investigated the effect of concomitant use of antiplatelet agents on anti-insulin antibodies production in type 2 diabetic patients treated with insulin analogues. Methods: Anti-insulin antibodies were measured in 150 type 2 diabetic patients using insulin analogue and 15 patients without insulin treatment but with antiplatelet agents. Among insulin treated patients, 62 had concomitant use of antiplatelet agents. Results: The overall positivity of anti-insulin antibodies in the insulin-treated patients was 25.3%. On the other hand, the positivity rate in those not on antiplatelet agents ( Conclusion: These results strongly suggest that antiplatelet agents affect the increased production rate of anti-insulin antibodies by insulin analogues and may have contributed to increased insulin dose requirement via positivity of anti-insulin antibodies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.